PTC
COGT icon

Private Trust Company’s Cogent Biosciences COGT Stock Holding History

Private Trust Company’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-54
Closed -$1.92K – 2623
2025
Q4 		$1.92K Buy
+54
New +$1.52K ﹤0.01% 2358

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Private Trust Company's COGT Position: Q1 2026 in Review

Private Trust Company sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 54 shares — an estimated $1.92K sold.

Private Trust Company first reported a position in COGT in Q4 2025 and held it in 1 quarter. The position peaked at $1.92K in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Private Trust Company reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
  • Private Trust Company sold 54 Cogent Biosciences shares in Q1 2026, an estimated $1.92K.
  • Private Trust Company first reported a position in Cogent Biosciences in Q4 2025 and held it in 1 quarter.
  • Private Trust Company's Cogent Biosciences position peaked at $1.92K in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Private Trust Company's 13F filing for Q1 2026, filed 30 Apr 2026.